



US 20210221843A1

(19) **United States**(12) **Patent Application Publication**
PELLECCHIA et al.(10) **Pub. No.: US 2021/0221843 A1**(43) **Pub. Date: Jul. 22, 2021**(54) **EPHA2 AGONISTS AND USES THEREOF****Publication Classification**(71) Applicant: **THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA,**
Oakland, CA (US)(51) **Int. Cl.**
C07K 7/06 (2006.01)**A61P 35/00** (2006.01)(72) Inventors: **Maurizio PELLECCIA,** San Diego,
CA (US); **Luca GAMBINI,** Riverside,
CA (US); **Ahmed SALEM,** Riverside,
CA (US); **Alexander ARONSON,**
Riverside, CA (US)(52) **U.S. Cl.**
CPC **C07K 7/06** (2013.01); **A61P 35/00**
(2018.01)(57) **ABSTRACT**(21) Appl. No.: **17/058,519**(22) PCT Filed: **Jun. 7, 2019**(86) PCT No.: **PCT/US19/36167**

§ 371 (c)(1),

(2) Date: **Nov. 24, 2020****Related U.S. Application Data**(60) Provisional application No. 62/682,079, filed on Jun.
7, 2018, provisional application No. 62/718,267, filed
on Aug. 13, 2018.

The methods and compositions of the disclosure provide for novel therapeutic compounds to treat obesity and aspects related thereto. Embodiments of the disclosure relate to oligonucleotide therapeutic (ONT) agents targeting miR-22 miRNA for the treatment of human obesity and related cardiometabolic disorders. Accordingly, aspects of the disclosure relate to modified nucleic acids, including locked nucleic acids, ethylene-bridged nucleotides, peptide nucleic acids, phosphorodiamidate morpholino oligonucleotides, and/or a 5'(E)-vinyl-phosphonate modification.

Specification includes a Sequence Listing.